The first person has been treated in the US Phase IIb clinical study of ReNeuron Group PLC’s (LON:RENE) CTX stem cell therapy candidate for stroke disability.
The mid-stage trial, called PISCES III, will see 110 patients with stable post-stroke disability given either the CTX therapy or a placebo.
WATCH: ReNeuron Group's phase IIb stroke trial kicks off with first patient treated
ReNeuron wants to show that the patients on its treatment see a “clinically significant” improvement on the Modified Rankin Scale – a measure of disability and dependence – after six months.
Top-line results are due early next year.
“We are delighted that the first subject has been treated in the PISCES III stroke clinical trial in the US with our CTX stem cell therapy candidate,” said chief executive Olav Hellebø.
“No therapeutic interventions are currently available to improve motor function and quality of life for disabled stroke patients. This important clinical trial moves us forward to potentially meeting this very significant unmet need.”
In midday trading, ReNeuron shares were 2% higher at 51,50p.
-- Adds share price --